Sunday, April 13, 2014 Quote below 'article on MANF'
"An important article on MANF has been just published by a group in Europe. The article shows that MANF is essential for survival of pancreatic beta cells.
http://www.cell.com/cell-reports/abstract/S2211-1247(14)00201-0

What is MANF? As I mentioned in my previous blog, we discovered that MANF (mesencephalic astrocyte-derived neurotrophic factor) was secreted from pancreatic beta cells and neurons when their endoplasmic reticulum calcium was depleted. We also claimed that MANF could be a promising biomarker and therapeutic target for Wolfram and type 1 diabetes.
http://wolframsyndrome.blogspot.com/2014/01/manf-wolfram-and-diabetes-what-is-manf.html

Why is this article important for us? This article supports our theory that MANF is an important therapeutic target for Wolfram and diabetes! I was really encouraged by this article. Currently, we are focusing on the clinical applications of MANF in Wolfram syndrome, diabetes, and other endoplasmic reticulum-related disorders. I hope we can bring you good news soon! "

http://wolframsyndrome.blogspot.com/2014/04/manf-wolfram-and-diabetes-part2.html

dsw you don't understand capital markets

explain facebook would you?

“The LymPro Test is potentially the first available blood test for Alzheimer’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus. “With this agreement, we expect to have initial data available in the third quarter of 2013, and now have the capabilities required to place LymPro on a path for commercialization in 2014.”

http://www.businesswire.com/news/home/20130613005183/en/Amarantus-Engages-BD-Biosciences-Development-Alzheimer%E2%80%99s-Diagnostic#.U3afevldUwo

Remember its Market cap is way below 100 million. It should be at 200 million market cap which right now is .25 cents.
It should be floating in that range of .20 to .30 cents really.
And with any guidance revenue wise, it will approach a dollar to
two dollars a share. At two dollars a share it would have a 1.6 billion market cap, and that is justified by revenue and earnings potential back dated from a future date. So if revenue can be 1.6 Billion in 5 years a two times revenue market cap is 3.2 Billion
and in todays market that price would be $4.65 per share, then we back date or adjust backwards to get to the 1-2 dollar range.
You see its all about guidance and revenue/profits future.

So don't get to excited about .08cents to .12 cents.

See China news release http://www.businesswire.com/news/home/20130619005044/en/Amarantus-Reports-Positive-Results-MANF-Neuroprotective-Properties#.U3aejfldUwo

Parkinson’s disease (PD)
I told some friends to buy, I bought very early AMBS today.

Parkinson’s disease (PD)
MANF was identified as a mesencephalic astrocyte-derived neurotrophic factor and, together with CDNF, forms a novel family of neurotrophic factors with distinct structures and functions as described in the previous sections. MANF, and to a lesser degree CDNF, display a spectrum of cellular activities that could translate to neuroprotective or restorative effects in PD.

Given its function and mechanism of expression in the heart, MANF was designated a “cardiomyokine”, which are defined as heart-derived, secreted proteins that affect cardiovascular
NON-CONFIDENTIAL
http://content.stockpr.com/amarantus/files/pdf/MANF+WhitePaper+2013-04-30+FINAL.pdf

I told some friends to buy, I bought very early AMBS

I only invested because of Dr. Rubinfield in this, then
after finding out more, I bought on its own merits.
Now, I"want a bit more. But I would like to here from the Gent,
anway.

What has Dr. Rubinstein been up to these days?

A founding Member of Amgen, is buying AMBS.
Ok, well some of you may not remember Amgen, a Darling on WallStreet went from Pennies to Number 2 BioTech.

Hmm, buying 208,000 shares ok, good sign. You know throw some
casino money in the pot what the heck.

Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD

Read more: Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD - FierceBiotech http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd#ixzz31nUILos9
Subscribe at FierceBiotech


China Update? Any idea.
post# 100982

http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd

How large can the MANF pipeline really be.

That's 500,000 x 3,000/per

Test is One point five Billion
In revenue

Lympro Pricing
Pricing levels will initially be negotiated directly with the payers based upon a dossier of information, that
may include the following: i) cost analysis of resources required to perform the test (both fixed and
variable); ii) amortization of the R&D investment to develop the test; iii) payment amounts determined by
other payers; iv) a health economic model reflecting the performance of the LymPro test; v) charges,
payment amounts and resources required for tests that may be comparable (crosswalk to other flow
cytometry type test) or otherwise relevant (i.e. gap fill to an imaging tests such as Avid
Radiopharmaceutical’s (now Lilly’s) Amyvid with an estimated $3,000-$5,000 per procedure in the US);
and vi) projected test volume and utilization data. Because private payers often use Medicare as a benchmark when developing their own payment policies the outcome of the Medicare rate setting process
could influence the payment rate set by other payers, consequently it is important to have a
comprehensive strategy in place for commercialization of the test prior to engaging with the payers.
Looking forward, it is anticipated that in the U.S. the emergence of a greater number of Managed Care &
Accountable Care organizations will drive Rx/Dx combination pricing discussions.

http://content.stockpr.com/amarantus/files/pdf/AMBS_LymPro_whitepaper_9may2013_2300.pdf

In a study entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" published in the journal Chinese Pharmacological Bulletin, the authors demonstrated that MANF had a pronounced effect in reducing tau hyperphosphorylation, reducing cell death, and improving overall cellular health in a preclinical models. Misfolded tau is a significant part of the pathophysiology of Alzheimer's disease and Chronic Traumatic Encephalopathy (CTE). The data in the study demonstrated:

Pretreatment with recombinant MANF can inhibit okadaic acid (OA) induced tau hyperphosphorylation in N2a cells;
Transfection of N2a cell with MANF cDNA also inhibits OA-induced tau hyperphosphorylation and supports cell viability;
Downregulation of MANF with siRNA promotes OA-induced toxicity.
In a study entitled "MANF Is Indispensable for the Proliferation and Survival of Pancreatic ß Cells" published in the journal Cell, the authors demonstrated that MANF is essential for the protection and proliferation of pancreatic beta islet cells. Beta islet cells degenerate via apoptosis in Type-1 Diabetes, Type-2 Diabetes and Wolfram Syndrome. The data in the study demonstrate:

MANF-deficient mice show growth retardation and a diabetic phenotype;
Beta cell mass is significantly reduced in MANF KO mice, caused by decreased proliferation and increased apoptosis;
Recombinant MANF significantly increases beta cell proliferation in vitro, while overexpression of MANF in the pancreas of diabetic mice enhances beta cell regeneration.
"The underlying mechanism of MANF appears to be truly unique, breakthrough biology with the potential to alter the practice of medicine in various large, underserved medical applications worldwide," said David A. Lowe, PhD and member of the Amarantus Board of Directors. "These two papers are particularly striking, given the emerging evidence for overlap in mechanisms involved in Alzheimer's disease and Diabetes. They provide further support for our work and raise the spectrum of future clinical developments, alongside Retinitis Pigmentosa and Parkinson's disease, into which our current development activities with MANF could feed. We are currently focused on the translation of this tremendous biological opportunity into clinical development and are making steady progress in this regard. We are encouraged the worldwide research community continues to increase the value of our IP position by publishing such important work and is conducting much of the proof of concept work related to this fascinating molecule as we move towards clinical trials."

http://globenewswire.com/news-release/2014/05/01/632354/10079549/en/Amarantus-Announces-Positive-Independent-Peer-Reviewed-Preclinical-Data-for-MANF-in-Alzheimer-s-and-Diabetes.html?print=1

That's why you buy a million shares.

ROCKETMAN One thing for sure, this stock is about as primed to pump up as any stock Ive seen. With lots of money sitting on the sidelines waiting for the day, the one day when Revenue can be projected with a real viable partner. It would be great if there were Two, one for US Markets, and the other one for European Markets. I'm talking about LymPro of course. But once that Candle is lit, this Rocketboy will become ROCKETMAN.

http://www.ncbi.nlm.nih.gov/gene/74840

The prestigious three-day, invitation-only annual B. Riley & Co. Investor Conference brings together a targeted audience of leading institutional investors, financial services professionals and other qualified investors. The conference will feature presentations by approximately 200 companies in a broad range of sectors, including technology, consumer, retail, energy, healthcare, media and entertainment and special situations. One-on-one meetings with company managements will be available for all client investors.

What do we have here? Blunt-MANF MANF vector containing the human gene sequencing through Invitrogen Corporation, sequencing and GenBank accession consistent human MANF gene, indicating that this plasmid can be used to amplify MANF gene

Buying early today, sorry if it bumped up a bit.

Its important to follow the Chinese Development linked to this post, there is high significance in that patent.

"Relieves Neuron Lesions Related to Parkinson Disease"
The fusion protein can enter cells after striding cell membranes, can pass through a blood brain barrier, has a nerve cell protection effect and can be used for relieving neuron lesions related to Parkinson disease.

Well we know the Chinese typically steal Intellectual Property (IP)
but this is whole sale robbery. I think GC needs to address this in his "BLOG" "Twitter" etc.,

F. Hoffmann-La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.

The company headquarters are located in Basel and the company has many pharmaceutical and diagnostic sites around the world - including: Pleasanton, CA; Vacaville, California, Oceanside, California, Branchburg, NJ; Indianapolis, Indiana; Florence, South Carolina; and Ponce, Puerto Rico in the US; Welwyn Garden City and Burgess Hill in the UK; Clarecastle in Ireland; Mannheim and Penzberg in Germany; Mississauga and Laval in Canada; Shanghai in China; Mumbai & Hyderabad in India; São Paulo, Brazil; Segrate, Milan in Italy; Johannesburg in South Africa; Karachi, Islamabad and Lahore in Pakistan. There are 26 manufacturing sites worldwide.[1]

The company owns the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals as well as the Tucson, Arizona based Ventana.

Roche's revenues during fiscal year 2013 were CHF 46.78 billion.[1] Roche is the fifth-largest pharma company worldwide.[2] Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares. Roche is one of the few companies increasing their dividend every year, for 2013 as the 27th consecutive year.[3]

F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[4]

http://en.wikipedia.org/wiki/Hoffmann-La_Roche

**UPDATES NEEDED GC >> See Link We need UPDATES

Billionaires Buy Merck Site to Build Swiss Biotech Campus

Swiss billionaires Hansjörg Wyss and Ernesto Bertarelli have bought the former building of drug company Merck Serono in Geneva, where they plan to set up a biotech research center with two local universities.

Merck Serono sold the building to a consortium called Campus Biotech, made up of the Bertarelli family, the Wyss Foundation, the University of Geneva (UNIGE), and the Swiss Federal Institute of Technology in Lausanne (EPFL). Bertarelli is, in fact, buying back the site of his former family business, biotech firm Serono, which he had sold to Merck in 2007.




http://news.sciencemag.org/people-events/2013/05/billionaires-buy-merck-site-build-swiss-biotech-campus

The human brain consists of 100 billion neurons , which provide the body constantly with information. It controls our thoughts and most of our movements. To understand the activity of the nerve cells in our brain in order to qualify for a long life as possible in creating good health , one of the main goals of brain specialists. According to estimates of the French governing body Fédération pour la recherche sur le cerveau (FRC), which organizes fundraising campaigns for funding research on a regular basis, the expenditure relating amounted to neurological and mental illnesses in 2010 alone, 800 billion euros. Worldwide over 36 million people are at Alzheimer diseased; Parkinson's is the second most common neurodegenerative disease in the world. Two billion people worldwide suffer from mental disorders.

https://www.humanbrainproject.eu/discover/the-project/overview


The Campus Biotech is a Swiss institution hosting research institutes and biotechnology companies. The Campus Biotech is located in the former Merck Serono building, in Geneva (Switzerland).[1]

http://en.wikipedia.org/wiki/Campus_Biotech


These organizations are in close proximity to Amarantus BioScience and its Scientists.

in preparation for the establishment of a Swiss affiliate.

Affiliate, indicates Partner correct?
What do you say, Novartis? Perhaps.

initiatives such as the Human Brain Project (HBP) and Campus Biotech. HBP is part of the Future and Emerging Technologies Flagship Program, a new initiative launched by the European Commission

HBP research will move to the Campus Biotech site in Geneva

As we prepare to interact with US and EU regulatory agencies regarding the proposed design of a Phase2/3 PD LID clinical trial for Eltoprazine, we believe it is important for Amarantus to have a presence in the emerging landscape of CNS biotechnology development in the Geneva area

http://finance.yahoo.com/news/amarantus-establishes-office-geneva-switzerland-123407290.html

Hope GC is not doing this anymore>>>> see link to post.

"They will be launching completed Lympro diagnostics in the US with Quest. Amarantus will retain 100% of the execution and marketing as a sole provider, no sale or partner, too much money for them to do it at this point. I am guessing Quest will have exclusivity with money up front back to AMBS. Overseas is different, nothing will be the same and the Geneva office is part of the marketing strategy to get to EMEA and launch in other countries. The US is the not only country with ALZ, why on earth they would just keep it here would be foolish. They will release it in Q3 and the data will conform to highest standards out there of recognition in accuracy. They will probably not need to dilute if Quest offers up enough to retain exclusivity rights. I suspect you will hear all of this in a marketing plan within the next few weeks, they literally will have to start advertising it soon to get awareness up, like within a few months max. You can't just drop this off at facilities, it will be a major process and they will be disclosing all of this well in advance. JDRF retains rights to allow disclosure on diabetes due to grant provision. Gerald has to let publications come out before he can do anything, so it appears. When JDRF PRs it, it will be way more impactful to AMBS, they reach millions, AMBS reaches thousands. I truly believe you're all finally there. You're looking at 1b+ in intake over the next few years due to lack of competition, keep that in mind when stressing about a .07 pps. They will get CMS approval, no question."

Take it for what its worth

The underlying mechanism of MANF appears to be truly unique, breakthrough biology with the potential to alter the practice of medicine in various large, underserved medical applications worldwide," said David A. Lowe, PhD and member of the Amarantus Board of Directors. "These two papers are particularly striking, given the emerging evidence for overlap in mechanisms involved in Alzheimer's disease and Diabetes. They provide further support for our work and raise the spectrum of future clinical developments, alongside Retinitis Pigmentosa and Parkinson's disease, into which our current development activities with MANF could feed. We are currently focused on the translation of this tremendous biological opportunity into clinical development and are making steady progress in this regard. We are encouraged the worldwide research community continues to increase the value of our IP position by publishing such important work and is conducting much of the proof of concept work related to this fascinating molecule as we move towards clinical trials."

This is what we need in July: If not run for the door

1) Positive LymPro Testing Data (mid 90s),
2) A Commercialization Partner,(Like Quest)
3) Revenue Guidance
4) A Commercialization Date (Sept, Oct, Nov?)
5) A Rest of World (ROW) Distribution Plan

I thought Money Train was leaving the Station?
Common you guys,

Get the Money Train Moving again. CHOOOOOOOOOOOO

"I SURVIED AMBS 700 MILLION DILUTION" << T-Shirt Logo

I"m now Rich it went to a Dollar.

Laughing Out Loud,
AMBS - WIll be .70 cents this fall, my plans.

I survived the 700million dilution How about Tshirt

How about some nice "Pens" that say LymPro.
A black T-shirt with Amarantus Logo on the shirt,
lets get a Brand Going Here Mr. GC. How about premium
Golf Shirts with small logo ?

Donate the proceeds to #C4CT

Need update on China Meeting. On the Blog Please.
Thank you

Can we get some AMBS Hats, Pens, T-Shirts, Golf Shirts?
From the Company Web site, along with Lympro Test order by mail,
donate the hat money to charity.

Analytical Performance Package (APP)

when the pilot data is publicly released by the Company, it will have been generated in our commercially validated assay.

The Company remains on track to complete CLIA-grade validation and preparation of the Analytical Performance Package (APP) for LymPro in the first half of 2014.



- See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/commercialization-track-2014-updating-lympro-test-progress/#sthash.MwT5GYMS.2HXik32c.dpuf

Great post should be permanently on board.
Great news, when it rockets up and the short term
holders sell, its great to get more or get in then.
This stock is going much much higher.

/ Begin Quote "We note that Eli Lilly acquired the Amyvid test by acquiring Avid Radiopharmaceuticals in 2010 for $300 million upfront and $500 million in backend consideration. The total deal price of $800 million is 25X the current market value for all of Amarantus BioScience Holdings, Inc., which includes the Amarantus Therapeutics division currently developing a mesencephalic astrocyte-derived neurotrophic factor (OTCPK:MANF) for the treatment of Parkinson's disease and other ischemic disorders." End Quote

Maybe some Swiss Francs,

Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis

http://seekingalpha.com/article/1347691-amarantus-lympro-could-be-a-game-changer-for-alzheimers-diagnosis

The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually.

Read more: Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD - FierceBiotech http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd#ixzz30nR29YnN
Subscribe at FierceBiotech


The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").

Read more: Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD - FierceBiotech http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd#ixzz30nRFgY8z
Subscribe at FierceBiotech

Final results are expected by summer 2014. Summer is June 21st

The solstice heralds the beginning of summer in the Northern Hemisphere. In 2014, the solstice falls on June 21 at 6:51 A.M. EDT.

http://www.almanac.com/content/first-day-summer-summer-solstice

"Final results are expected by summer 2014. may rapidly lead to clinical application of the findings."


INTERIM PROGRESS REPORT

We have completed experiments in parkinsonian dyskinetic preclinical models. Results have so far suggested that co-administration of the A2A receptor antagonist Preladenant and the 5-HT1 receptor agonist Eltoprazine is highly effective in suppressing already established levodopa-induced dyskinesia, while easing the motor impairments in a model of Parkinson´s disease. This approach is currently being tested in MPTP-treated models. Further experiments in the initial model are also ongoing to address whether this treatment can prevent development of dyskinesia when given starting from the first levodopa dose. Final results are expected by summer 2014.


https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1030